Study Design and Rationale for Investigating Phosphodiesterase type 5 Inhibition for the Treatment of Pulmonary Hypertension Due to Chronic Obstructive Lung Disease: The TADA-PHiLD (TADAlafil for Pulmonary Hypertension Associated with Chronic Obstructive Lung Disease) Trial
2004 ◽
Vol 97
(2)
◽
pp. 187-192
◽
1989 ◽
Vol 9
(10)
◽
pp. 393
2001 ◽
Vol 164
(2)
◽
pp. 219-224
◽
1994 ◽
Vol 23
(4)
◽
pp. 517-524
◽